Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities

Abstract Purpose The 34-gene classifier, ClearCode34, identifies prognostically distinct molecular subtypes of clear cell renal cell carcinoma (ccRCC) termed clear cell A (ccA) and clear cell B (ccB). The primary objective of this study was to describe clinical characteristics and comorbidities of r...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2016-03, Vol.34 (3), p.122.e1-122.e7
Main Authors: Haake, Scott M., M.D, Brooks, Samira A., Ph.D, Welsh, Eric, Ph.D, Fulp, William J., M.S, Chen, Dung-Tsa, Ph.D, Dhillon, Jasreman, M.D, Haura, Eric, M.D, Sexton, Wade, M.D, Spiess, Philippe E., M.D, Pow-Sang, Julio, M.D, Rathmell, W. Kimryn, M.D., Ph.D, Fishman, Mayer, M.D., Ph.D
Format: Article
Language:English
Subjects:
Aged
Biomarkers, Tumor - genetics
Carcinoma, Renal Cell - classification
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - secondary
Clear cell renal cell carcinoma
ClearCode34
Comorbidity
Diabetes mellitus
Female
Follow-Up Studies
Humans
Kidney Neoplasms - classification
Kidney Neoplasms - genetics
Kidney Neoplasms - pathology
Male
Middle Aged
Multivariate Analysis
Neoplasm Metastasis
Neoplasm Recurrence, Local - classification
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Obesity
Prognosis
Retrospective Studies
Survival Rate
Transcriptome
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Purpose The 34-gene classifier, ClearCode34, identifies prognostically distinct molecular subtypes of clear cell renal cell carcinoma (ccRCC) termed clear cell A (ccA) and clear cell B (ccB). The primary objective of this study was to describe clinical characteristics and comorbidities of relevance in patients stratified by ClearCode34. Patients and methods In this retrospective analysis, 282 patients from Moffitt Cancer Center with ccRCC with gene expression analyses of the primary tumor were identified and ClearCode34 was applied to identify tumors as ccA or ccB. The medical record and institutional databases were queried to define patient characteristics, comorbidities, and outcomes. Results We validated in this external cohort the superior overall survival, cancer-specific survival, and recurrence-free survival of ccA patients relative to ccB patients ( P
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2015.09.015